Abstract
Thioridazine is a phenothiazine drug which has previously been extensively used for its antipsychotic properties as it is associated with a low risk of extra-pyramidal side-effects. There is good evidence to suggest that, in common with other phenothiazine drugs, thioridazine has important anti-microbial activity and is a potential candidate for development as an anti-microbial drug against multi-resistant organisms, including drug-resistant strains of Mycobacterium tuberculosis. The clinical pharmacology and toxicity profile of thioridazine are reviewed in this article and the implications for future drug development along with the patent are discussed.
Keywords: Antimicrobial, cardiotoxicity, extra-pyramidal syndrome, QT prolongation, thioridazine, METABOLISM OF THIORIDAZINE, CYP2C19, Anti-psychotic activity, arrhythmogenic effect
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Infectious Disorders - Drug Targets
Letters in Drug Design & Discovery
Current HIV Research
Related Books
Marine Biopharmaceuticals: Scope and Prospects
COVID 19 – Monitoring with IoT Devices
Frontiers in Clinical Drug Research: Anti-Infectives
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents
Recent Trends and The Future of Antimicrobial Agents - Part 2
COVID-19: Origin, Impact and Management (Part 2)
Frontiers in Anti-Infective Drug Discovery
COVID-19: Origin, Impact and Management, Part 1
Toll-Like Receptors in Vector-borne Diseases
15